kabutan

Heartseed Inc.(219A) Summary

219A
TSE Growth
Heartseed Inc.
1,922
JPY
-83
(-4.14%)
Dec 12, 3:30 pm JST
12.33
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
1,960
Dec 12, 11:58 pm JST
Summary Chart Historical News Financial Result
PER
223.2
PBR
6.10
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:09 am
2,205 JPY 14.17 USD
Previous Close Dec 11
2,005 JPY 12.84 USD
High Dec 12, 9:10 am
2,293 JPY 14.73 USD
Low Dec 12, 3:16 pm
1,901 JPY 12.20 USD
Volume
2,821,000
Trading Value
5.92B JPY 0.04B USD
VWAP
2097.27 JPY 13.46 USD
Minimum Trading Value
192,200 JPY 1,233 USD
Market Cap
0.04T JPY 0.28B USD
Number of Trades
11,173
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
High
1-Year Average
4,585
1-Year High Oct 2, 2025
50,688
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 820,300 2,004,400 2.44
Nov 28, 2025 758,800 2,063,100 2.72
Nov 21, 2025 765,000 2,090,700 2.73
Nov 14, 2025 768,600 2,141,700 2.79
Nov 7, 2025 780,800 2,302,500 2.95
Company Profile
Heartseed Inc. engages in the research and development of regenerative medicine products using iPS cells for cardiac regeneration.
Sector
Pharmaceuticals
Heartseed Inc. is a regenerative medicine venture originating from Keio University. The company is advancing the development of "cardiac regenerative medicine," a treatment method that involves transplanting micro-tissues (cardiac spheroids) derived from iPS cell-based cardiomyocytes into the heart, aiming to establish safety and efficacy. Heartseed possesses proprietary technologies, including techniques for producing high-purity cardiomyocytes and transplantation devices. With a vision for global expansion of cardiac regenerative medicine using allogeneic iPS cell-derived cardiac spheroids, the company entered into an exclusive worldwide technology partnership and licensing agreement with Novo Nordisk, a global pharmaceutical giant headquartered in Denmark, in May 2021.